ºîÀ®¡§ 1999/11/25 ¾®¸ý¡¡ÀµÉ§
¥Ç¡¼¥¿Èֹ桡¡¡¡¡¡§030151
°À¥ê¥ó¥Ñ¼ð¤ÎÊü¼ÍÀþ¼£ÎŤˤĤ¤¤Æ¡Ý¥ê¥ó¥ÑÀᳰ¡´ï½éȯÎã¡Ý
ÌÜŪ¡¡¡¡¡¡¡¡¡¡¡¡¡§¥ê¥ó¥ÑÀᳰ¡´ï½éȯ¤Î°À¥ê¥ó¥Ñ¼ð¤ËÂФ·¤ÆÊü¼ÍÀþ¼£ÎŤ¬¤É¤Î¤è¤¦¤ËÌòΩ¤Ä¤«¤ò¾Ò²ð¤¹¤ë
Êü¼ÍÀþ¤Î¼ïÊÌ¡¡¡¡¡§¥¨¥Ã¥¯¥¹Àþ,ÅÅ»Ò
Êü¼ÍÀþ¸»¡¡¡¡¡¡¡¡¡§Ä¾Àþ²Ã®´ï¡¦¥ê¥Ë¥¢¥Ã¥¯(Linear Accelerator)
ÀþÎÌ¡ÊΨ¡Ë¡¡¡¡¡¡¡§20-50 Gy
ÍøÍÑ»ÜÀß̾¡¡¡¡¡¡¡§Êü¼ÍÀþ¼ðáç°å¤Î¤¤¤ëÊü¼ÍÀþ¼£ÎÅ»ÜÀß
±þÍÑʬÌî¡¡¡¡¡¡¡¡¡§°å³Ø¡¢¤¬¤ó¼£ÎÅ
³µÍס¡¡¡¡¡¡¡¡¡¡¡¡§
¡¡¥ê¥ó¥ÑÀá°Ê³°¤Ë½éȯ¤¹¤ë°À¥ê¥ó¥Ñ¼ð¤Ï¡¢Éô°ÌÊ̤ËMarginal zone B cell Lymphoma¤äNK-T cell Lymphoma¤Ê¤É¤ÎÆÃ¼ì¤ÊÉÂÍý°¡Ê¬Îà·¿¤Îȯ¾ÉÉÑÅÙ¤¬Â¿¤¯¡¢¤Þ¤¿¸Â¶ÉÀ¤Ç¤¢¤ë¤¦¤Á¤Ï¸Ç·Á¤¬¤ó¤È¤·¤Æ¤ÎÀ¼Á¤òͤ¹¤ë¡£¤³¤ì¤é¤¬²½³ØÎÅË¡¤ËÄñ¹³À¤Ç¤¢¤ë¤³¤È¤â¤¢¤Ã¤Æ¡¢Êü¼ÍÀþñÆÈ¼£ÎŤ¬ÁªÂò¤µ¤ì¤ë¾ì¹ç¤¬Â¿¤¤¡£Àá³°À¥ê¥ó¥Ñ¼ð¤Î¤¦¤ÁÂåɽŪ¤Ê°ß¡¢¹Ã¾õÁ£¡¢ÎÞÁ£·ëËì¡¢ÂñÕÁ£¤Ë¿¤¤Mucosa Associated Lymphoid Tissue Lymphoma (MALT Lymphoma)¤ÈÉ¡¹Ð¤Ë¿¤¤Nasal NK-T cell Lymphoma¤Ë¤Ä¤¤¤Æ³µÀ⤹¤ë¡£
¾ÜºÙÀâÌÀ¡¡¡¡¡¡¡¡¡§
1. Marginal zone B cell Lymphoma (Extranodal type:Mucosa Associated lymphoid Tissue Lymphoma¡§Stage I, II)
¡¡°ß¡¦¹Ã¾õÁ£¡¦ÎÞÁ£¡¦·ëË졦ÂñÕÁ£¤Ê¤É¡¢¤½¤â¤½¤âÀµ¾ï¤Ê¡´ïÆâ¤Ë¥ê¥ó¥ÑÁÈ¿¥¤¬¤Ê¤¤½ê¤Ë¥ê¥ó¥Ñµå¤¬ËýÀŪ¤Ë¿»½á¤¹¤ëÉÂÂÖ¡¢Î㤨¤Ð¥Ø¥ê¥³¥Ð¥¯¥¿¡¦¥Ô¥í¥ê¶Ý(H.Pylori)¤ÎËýÀ´¶À÷¡¦¶¶ËÜÉ¡¦¥·¥§¡¼¥°¥ì¥ó¾É¸õ·²¤Ê¤É¤ò·Àµ¡¤Ë¡¢Â¿Ãʳ¬È¯¤¬¤ó²áÄø¤ò·Ð¤ÆÈ¯¾É¤·¡¢Ä¹¤¤·Ð²á¤È¤È¤â¤Ë°ÀÅÙ¤¬¹â¤Þ¤ë¤³¤È¤¬¤¢¤ë¡£
¡¡°ß¤Ç¤Ï¡¢Í£°ì¤ÎºÙ¶ÝÀ¹³¸¶¤Ç¤¢¤ëH.Pylori¤Ë¤è¤êMALT¤¬È¯Ã£¤¹¤ë¡£MALT¤ÎÃæ¤ÇH.PyloriÆÃ°ÛÀT¥ê¥ó¥Ñµå¤ËÀ©¸æ¤µ¤ì¤Ä¤Ä¤â¡¢B¥ê¥ó¥Ñµå¤ÏClonal¤ËÁý¿£¤·Early Low grade MALT Lymphoma ¤ËÊÑÍÆ¤¹¤ë¡£¤³¤Î»þ´ü¤Ç¤Ï¡¢H. Pylori½ü¶ÝÎÅË¡¤Ë¤è¤êÎ×¾²Åª¤Ë¤Ï´²²ò¤¹¤ë¡£¤µ¤é¤Ë¿Ê¹Ô¤·¤¿Late Low grade MALT lymphoma¤Ç¤Ï¡¢¤â¤Ï¤äH. Pylori½ü¶Ý¤ËÈ¿±þ¤»¤º¡¢°ßÇ´Ë줫¤é¿¼Éô¤Ë¿»½á¤·°ß¼þ°Ï¥ê¥ó¥ÑÀá¤Ë¤âž°Ü¤¹¤ë²ÄǽÀ¤¬¤¢¤ë¡£Memorial Sloan-Kettering Hospital ¤«¤é¡¢MALT lymphoma¤Ë¤Ï30Gy¤ÎÊü¼ÍÀþÎÅË¡¤Ç100%¤ÎCRΨ¤¬Êó¹ð¤µ¤ì¤¿(¿Þ1¡¢Ê¸¸¥1)¡£¤µ¤é¤Ë°äÅÁ»Ò°Û¾ï¤òÀѤ߽Ťͤơ¢High grade transformed MALT lymphoma¤¬À¸¤¸¤Î¤Ç¡¢°ß¸¶È¯¤ÎDiffuse Large B cell Lymphoma(DLBL)¤ÎÃæ¤Ë¤Ï¡¢transformed MALT lymphoma¤ò´Þ¤à¤È¤¤¤¦¸«²ò¤¬¤¢¤ë¡£DLBL¤ËÂФ·¤ÆÃ»´ü²½³ØÎÅË¡(CHOP x3)¸å¤ËÊü¼ÍÀþ¾È¼Í¤ò¹Ô¤¦¼£ÎÅÊý¿Ë¤¬ºÎÍѤµ¤ì¡¢°ß¤ò²¹Â¸¤·¤¿Îɹ¥¤Ê¼£ÎÅÀ®ÀÓ¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡£

¿Þ1¡¡°ßMALT¥ê¥ó¥Ñ¼ð¤ÎÊü¼ÍÀþ¼£ÎÅÀ®ÀÓ ¡Ê¸¶ÏÀʸ1¤è¤ê°úÍÑ¡£¡¡Reproduced from Journal of Clinical Oncology, 1998; 16(5):1916-1921, Figure 1 (p.1918), Schechter NR, Portlock CS, Yahalom J., Treatment of Mucosa-associated Lymphoid Tissue Lymphoma of the Stomach with Radiation Alone; Copyright(1998), with permission from Lippincott-Raven Publishers.¡Ë
¡¡Á´¹Ã¾õÁ£¥ê¥ó¥Ñ¼ð¤ÎÌó15-20%¤¬MALT lymphoma¤Ç¤¢¤ê¡¢Ìó30%¤¬transformed MALT lymphoma(with DLBL)¡¢Ìó50%¤¬DLBL¤Ç¤¢¤ë¡£½¾Íè¹Ã¾õÁ£¥ê¥ó¥Ñ¼ð¤Ç¤Ï¡¢ÉÂÁã¤ÎÂ礤µ¤¬¼£ÎÅÀ®ÀӤ˴ط¸¤¹¤ë¤µ¤ì¤Æ¤¤¿¤¬¡¢Â礤µ¤Ê¤ÉPrognostic Factor¤ÈMALT lymphoma +/- DLBL¤ÎÈæÎ¨¤Ë¤è¤Ã¤Æ¡¢5ǯÎßÀÑÀ¸Â¸Î¨40-75%¤È5ǯÈóºÆÇ³À¸Â¸Î¨38-64%¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë(ʸ¸¥2)¡£°ìÈ̤ËNon-Bulky¤Ç¤¢¤ëMALT lymphoma¤Ë¤Ï¡¢35-45Gy¤ÎÊü¼ÍÀþñÆÈ¼£ÎŤ¬Å¬±þ¤È¤Ê¤ë¡£Bulky¤ÊHigh grade transformed MALT lymphoma¤ËÂФ·¤ÆÊü¼ÍÀþñÆÈ¼£ÎŤǽ½Ê¬¤«¡¢²½³ØÎÅË¡¤ÎÊ»ÍѤ¬É¬Íפ«º£¸å¤Î¸¡Æ¤²ÝÂê¤Ç¤¢¤ë¡£
¡¡ÎÞÁ£¡¦·ëËì¤Ê¤É´ããÝÉí°´ï½éȯ¤Î¥ê¥ó¥Ñ¼ð¤Î50-70%¤ÏMALT lymphoma¤Ç¤¢¤ê¡¢¤·¤Ð¤·¤Ðξ´ãÀ¤Ç¤¢¤ë¡£20-30GyÄøÅÙ¤ÎÊü¼ÍÀþ¼£ÎÅñÆÈ¤Ç95%°Ê¾å¤Î5ǯÈóºÆÇ³À¸Â¸Î¨¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë(¿Þ2¡¢Ê¸¸¥3)¡£µ©¤ËDiffuse Large B cell Lymphoma¤¬È¯¾É¤¹¤ë¤Î¤ÇÃí°Õ¤¬É¬ÍפǤ¢¤ë¡£ÌÖËì¾É¡¢ÇòÆâ¾ã¡¢ÎÞÁ£µ¡Ç½Äã²¼¤Ë¤è¤ë´¥ÁçÀ³Ñ·ëËì±ê¤Ê¤É¤ÎÊü¼ÍÀþ¤Ë¤è¤ëͳ²È¿±þ¤òµ¯¤³¤µ¤Ê¤¤¤è¤¦¤Ê¾È¼ÍÊýË¡¤ò¤È¤ëɬÍפ¬¤¢¤ë¡£

¿Þ2¡¡´ããÝMALT¥ê¥ó¥Ñ¼ð¤ÎÊü¼ÍÀþ¼£ÎÅÀ®ÀÓ ¡Ê¸¶ÏÀʸ3¤è¤ê°úÍÑ¡£¡¡Reproduced from International Journal of Radiation Oncology Biology Physics 1993; 26(1):59-66, Figure 3 (p.60), Smith MC, Donaldson SS., Radiotherapy is successful treatment for orbital lymphoma; Copyright(1993), with permission from Elsevier Science.¡Ë
¡¡ÂñÕÁ£¤ÎMALT lymphoma¤Ë¤Ï¡¢35-45Gy¤ÎÊü¼ÍÀþñÆÈ¼£ÎŤǡ¢100%¤ÎCRΨ¤È90%¤Î5ǯÎßÀÑ¡¦ÈóºÆÇ³À¸Â¸Î¨¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡£
2.¡¡Nasal NK-T cell Lymphoma
¡¡ÆüËܤǤϡ¢É¡¹Ð¤«¤é¤ÏNasal NK-T cell Lymphoma¤¬¡¢ÉûÉ¡¹Ð¤«¤é¤ÏDLBL¤¬Â¿¤¯È¯¾É¤¹¤ë¡£Nasal NK-T cell Lymphoma¤Ï¡¢Å쥢¥¸¥¢¿Í¤Ë¿¤¯¡¢ÌȱÖÀ÷¿§¤ÇCD56(NCAM)+¤Ç¤¢¤ê¡¢Ebstein Barr Virus¤¬È¯¥¬¥ó¤Ë¿¼¤¯´Ø¤ï¤Ã¤Æ¤¤¤ë(ɽ1¡¢Ê¸¸¥3)¡£cStage I¤Ç¤¢¤ì¤Ð¡¢Â¾¤ÎNK-T cell Lymphoma (blastoid, etc)¤ÈÈæ³Ó¤·¤ÆÍ½¸å¤¬¤è¤¯¡¢¼£ÎÅÀ®ÀÓ¤Ï50-80%¤Ç¤¢¤ë¡£NK cell¤Ï¡¢¥ê¥ó¥Ñµå¤ÎÃæ¤Ç¤ÏÊü¼ÍÀþ´¶¼õÀ¤¬Ë³¤·¤¯¡¢50Gy°Ê¾å¤ÎÀþÎ̤¬¶É½êÀ©¸æ¤ËɬÍפȤµ¤ì¤ë¡£²½³ØÎÅË¡¤Ïdose intensity ¤ò¾å¤²¤Æ¤â̵¸ú¤Ç¤¢¤ë¤³¤È¤¬Â¿¤¯¡¢Êü¼ÍÀþ¾È¼Í¤òÀè¹Ô¤µ¤»¤ë¤«(French study)¤Ç¤¤ë¤À¤±Áᤤ»þ´ü¤Ë¹Ô¤¦(Hong Kong study)¤³¤È¤¬½ÅÍפǤ¢¤ë¡£°ìö¡¢Á´¿È²½¤¹¤ë¤È¼£Ìþ¤Ï¤Ê¤«¤Ê¤«º¤Æñ¤Ç¤¢¤ë¡£É¡¹Ð¡¿ÉûÉ¡¹Ð¤ò¤¤Á¤ó¤È¼£ÎŤ·´ãµå¡¿Ç¾¤Ê¤É¤òËɸ¤ë¤Ë¤Ï3D conformal radiotherapy¤¬É¬ÍפǤ¢¤ë¡£
ɽ1¡¡É¡¹Ð¥ê¥ó¥Ñ¼ð¤Î¼£ÎÅÀ®ÀÓ ¡Ê¸¶ÏÀʸ4¤è¤ê°úÍÑ¡£¡¡Reproduced from Journal of Clinical Oncology 1998; 16(1):70-77, Table 1 (p.73), Cheung MMC, Chan JKC, Lau WH, et.al.., Primary Non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features tumor immunophenotype, and treatment outcome in 113 patients; Copyright(1998), with permission from Lippincott-Raven Publishers.¡Ë
---------------------------------------------------------------------------------------
Prognostic Factor Complete Response 2-Year Disease-Free 2-Year Overall
Rate(%) Survival Survival
---------------------------------------------------------------------------------------
Sex
Male 66.7 45.1 55.4
Female 64.7(P=.337)* 25.7(P=.101)¢÷ 36.8(P=.228)
(multivariate P=.105)¢ø (multivariate P=.165)
Age,years
¡ã60 62.7 44.7 54.1
¡æ60 73.7(P=.987) 32.3(P=.312) 44.2(P=.035)
(multivariate P=.522) (multivariate P=.057)
Stage
€€ 75.4 47.7 59.0
€€ 72.4 41.4 48.3
€€ 37.5 12.5 37.5
€€ 23.1(P=.009) 13.3(P=.003) 20.0(P=.008)
(multivariate P=.057) (multivariate P=.012)
B symptoms
No 72.2 42.8 54.9
Yes 38.1(P=.007) 22.7(P=.072) 27.3(P=.043)
(multivariate P=.404) (multivariate P=.130)
Immunophenotype
NK/T 56.0 31.0 43.0
T cell 69.6 52.3 62.5
B cell 76.3(P=.126) 40.9(P=.102) 50.0(P=.140)
(multivariate P=.007) (multivariate P=.006)
WF group
DSCC 90.9 50.0 81.8
DMC 68.2 48.3 55.6
DLC/LCI 58.9(P=.113) 29.6(P=.023) 38.5(P=.123)
(multivariate P=.080) (multivariate P=.141)
Treatment
Radiation alone 84.0 59.7 64.0
Curative chemotherapy 64.6(P=.113) 36.7(P=.221) 50.6(P=.277)
¡Þradiation (multivariate P=.159) (multivariate P=.085)
---------------------------------------------------------------------------------------
*Complete response rates compared using ¦Ö2test
¢÷Univariate analysis
¢øMultivariate analysis
¥³¥á¥ó¥È¡¡¡¡¡¡¡¡¡§
¡¡°äÅÁ»Ò³Ø¤äʬ»ÒÀ¸Êª³Ø¡¢ÌȱֳؤοÊÊâ¤òÈ¿±Ç¤·¤Æ¡¢°À¥ê¥ó¥Ñ¼ð¤Ë´Ø¤¹¤ë°å³Ø¸¦µæ¤Ï¡¢ÉÂÍý³Ø¡¢¿ÇÃdzء¢¼£ÎųؤʤÉÁ´¤Æ¤ÎÎΰè¤ÇµÞ®¤Ë¿ÊÊ⤷¤Æ¤¤¤ë¡£Ç¯¡¹¿·¤·¤¤¼À´µ³µÇ°¤¬À¸¤Þ¤ì¡¢Êü¼ÍÀþ¼£ÎŤ¬¡¢²¿¤é¤«¤ÎÌò³ä¤ò²Ì¤¿¤»¤ë²ÄǽÀ¤¬¤¢¤ë¡£ÆÃ¤Ë¸Â¶É´ü¤ÎHodgkin's Lymphoma¤äIndolent Lymphoma¤Î¼£ÎŤˤª¤±¤ëÊü¼ÍÀþÎÅË¡¤ÎÌò³ä¤ÏÂ礤¤¡£¤³¤ì¤é¤Î¼À´µ¤Ç¤Ï¡¢¸Ä¡¹¤Î´µ¼Ô¤ÎǯÎá¤Ê¤É¤ÎPrognostic Factor¤äQOL¤ò½½Ê¬¸¡Æ¤¤·¼£ÎÅÊý¿Ë¤òΩ°Æ¤¹¤ë¤È¡¢Êü¼ÍÀþñÆÈ¼£ÎŤ¬ÁªÂò¤µ¤ì¤¦¤ë¡£
¸¶ÏÀʸ£± Data source 1¡§
Treatment of Mucosa-associated Lymphoid Tissue Lymphoma of the Stomach with Radiation
Alone
Schechter NR, Portlock CS, Yahalom J.
Memorial Sloan-Kettering Cancer Center
Journal of Clinical Oncology 1998; 16(5):1916-1921.
¸¶ÏÀʸ£² Data source 2¡§
The Lymphomas
Canellos GP, Lister TA, Sklar JL
Harvard Medical School
WB Saunders Company (Philadelphia) 1998
¸¶ÏÀʸ£³ Data source 3¡§
Radiotherapy is successful treatment for orbital lymphoma.
Smith MC, Donaldson SS.
Stanford University
International Journal of Radiation Oncology Biology Physics 1993; 26(1):59-66.
¸¶ÏÀʸ£´ Data source 4¡§
Primary Non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features tumor
immunophenotype, and treatment outcome in 113 patients
Cheung MMC, Chan JKC, Lau WH, et.al.
Queen Elizabeth Hospital
Journal of Clinical Oncology 1998; 16(1):70-77.
»²¹Í»ñÎÁ£± Reference 1¡§
¥È¥Ô¥Ã¥¯¥¹¡¡Æ¬ðôÉôÎΰè¤Î°À¥ê¥ó¥Ñ¼ð¡¡3.¡¡¿ÇÃǤȼ£ÎÅ-Êü¼ÍÀþ²Ê¤ÎΩ¾ì¤«¤é-
ÃÓÅÄ¡¡²ú
¹ñΩ¤¬¤ó¥»¥ó¥¿¡¼É±¡
¼ªÉ¡°ö¹¢²Ê¡¦Æ¬ðôÉô³°²Ê¡¡Âè66´¬¡¡Âè3¹æ¡¡1994ǯ3·î20Æüȯ¹Ô
»²¹Í»ñÎÁ£² Reference 2¡§
Clinicophathologic study of nasal NK-cell lymphoma among the Japanese.
Nakamura S, Katoh E, Koshikawa T, et.al.
Southwest Oncology Group
Pathol Int 1997;47:38-53.
¥¡¼¥ï¡¼¥É¡§°À¥ê¥ó¥Ñ¼ð(Malignant Lymphoma)¡¢¥Û¥¸¥¥ó¥ê¥ó¥Ñ¼ð(Hodgkin's Lymphoma)¡¢Èó¥Û¥¸¥¥ó¥ê¥ó¥Ñ¼ð(Non-Hodgkin's Lymphoma)¡¢Êü¼ÍÀþ¼£ÎÅ(Radiation Therapy)¡¢¥ê¥Ë¥¢¥Ã¥¯(Linear Accelerator)¡¢¾È¼Í(Radiation)¡¢¾È¼ÍÌî(Radiation Field)¡¢¾È¼ÍÀþÎÌ(Radiation Dose)¡¢Ê¬³ä¾È¼Í(Fractionation)¡¢²½³ØÎÅË¡(Chemotherapy)
ʬÎॳ¡¼¥É¡§030201